Egetis Therapeutics AB Stock
Stocks
EGTX
SE0003815604
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
14:27:05 16/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 11.13 SEK | -0.62% |
|
0.00% | +108.24% |
| 11-12 | Lannebo Health and New Technology rose 7.2 percent in October - Bonesupport and Cellavision among the winners | FW |
| 11-11 | Sand Grove Capital increases stake in Egetis Therapeutics | FW |
| Market Cap | 5.21B 517M 469M 434M 391M 737M 48.77B 763M 2.06B 26.05B 1.94B 1.9B 82.69B | P/E 2026 * |
132x | P/E 2027 * | -43.3x |
|---|---|---|---|---|---|
| Enterprise Value | 4.28B 425M 385M 356M 321M 605M 40.04B 627M 1.7B 21.39B 1.59B 1.56B 67.89B | EV / Sales 2026 * |
37.9x | EV / Sales 2027 * | 8.77x |
| Free-Float |
37.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| EGTX | Delayed | |
| 0ABW | Delayed | ||
| PDPHF | Delayed | ||
| Real-time | |||
| P0F | Delayed | ||
| P0F | Real-time | ||
| P0F | Delayed | ||
| 0ABW | Real-time |
Last Transcript: Egetis Therapeutics AB
| 1 day | -0.62% | ||
| Current month | +10.54% | ||
| 1 month | +20.35% | ||
| 3 months | +56.84% | ||
| 6 months | +65.48% | ||
| Current year | +108.24% |
| 1 week | 11.1 | 11.2 | |
| 1 month | 8.96 | 11.2 | |
| Current year | 4.23 | 11.2 | |
| 1 year | 3.62 | 11.2 | |
| 3 years | 3.02 | 11.2 | |
| 5 years | 3 | 11.2 | |
| 10 years | 3 | 22.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 16/06/2017 | |
Yilmaz Mahshid
DFI | Director of Finance/CFO | 47 | 31/12/2017 |
Tiago Nune
CTO | Chief Tech/Sci/R&D Officer | - | 01/05/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 65 | 01/01/2017 | |
Mats Blom
CHM | Chairman | 61 | 06/05/2024 |
Behshad Sheldon
BRD | Director/Board Member | 63 | 01/01/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/2/26 A | Sell | Executive/Senior Manager | -594 | 0.0001% | ||
| 8/31/26 A | Exercice | Chief Financial Officer | 1,099 | 0.0002% | ||
| 8/31/26 A | Buy | Chief Operating Officer | 1,099 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.62% | 0.00% | +89.44% | +126.25% | 517M | ||
| -2.69% | -0.48% | +53.97% | +66.82% | 66.33B | ||
| +0.18% | +3.09% | +11.08% | +95.60% | 60.62B | ||
| +1.11% | +2.03% | +24.73% | +90.43% | 55.5B | ||
| +0.14% | +2.35% | +13.86% | +111.94% | 47.58B | ||
| -2.21% | -2.47% | +20.18% | +28.81% | 43.69B | ||
| -2.30% | -10.40% | +154.30% | +707.36% | 37.27B | ||
| +2.15% | +1.42% | +14.58% | +48.71% | 36.57B | ||
| +3.03% | -3.17% | +79.45% | +61.43% | 32.22B | ||
| +2.62% | +5.90% | -37.29% | +386.59% | 26.58B | ||
| Average | +0.14% | +0.12% | +42.43% | +172.39% | 41B | |
| Weighted average by Cap. | -0.09% | +0.20% | +37.02% | +153.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 113M 11.22M 10.17M 9.4M 8.48M 15.99M 1.06B 16.55M 44.79M 565M 42.1M 41.2M 1.79B | 512M 50.85M 46.08M 42.62M 38.45M 72.47M 4.79B 75.02M 203M 2.56B 191M 187M 8.13B |
| Net income | 414M 41.12M 37.26M 34.46M 31.09M 58.6M 3.88B 60.66M 164M 2.07B 154M 151M 6.57B | -42.62M -4.23M -3.84M -3.55M -3.2M -6.03M -399M -6.25M -16.9M -213M -15.88M -15.55M -677M |
| Net Debt | -932M -92.56M -83.88M -77.58M -70M -132M -8.73B -137M -370M -4.66B -347M -340M -14.8B | -720M -71.51M -64.81M -59.94M -54.08M -102M -6.74B -106M -286M -3.6B -268M -263M -11.43B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/11/26 | SEK 11.12 | -0.71% | 844,215 |
| 13/11/26 | SEK 11.20 | +0.72% | 2,237,972 |
| 12/11/26 | SEK 11.12 | 0.00% | 2,578,051 |
| 11/11/26 | SEK 11.12 | +0.18% | 5,182,684 |
| 10/11/26 | SEK 11.10 | -0.18% | 4,722,428 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- EGTX Stock
Select your edition
All financial news and data tailored to specific country editions
















